Span Divergent Ltd.
(Formerly Span Diagnostics Ltd.)
9th Floor, Rajhans Bonista,
Behind Ram Chowk, Ghod Dod Road,
Surat - 395 007, Gujarat, India
Phone: +91 261 266 32 32
E-Mail: contact@span.in

Date: November 05, 2026

To,
Listing Compliance Department
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Tower, 25th Floor
Dalal Street,
Mumbai – 400 001

Scrip Code: 524727

Subject: Outcome of the Board Meeting – November 05, 2026

Respected Sir,

We are pleased to inform you that:

1. At the meeting of Board of Directors held on Thursday, November 05, 2026, the Board of Directors has approved the Un-audited Integrated Financial Results (Both Standalone & Consolidated) of the Company for the Quarter and Half Year ended September 30, 2026, of the Current Financial Year 2026 - 2027 as recommended by the Audit Committee along with Limited Review Report of the Statutory Auditors of the Company, M/s. Y B Desai & Associates, Surat. A copy of the said Un-audited Financial Results (Standalone and Consolidated) containing disclosures required under Regulation 30, 33 and other provisions of the Listing Regulations as applicable along with the Limited Review Report by the Statutory Auditor of the company is enclosed.

2. At the meeting of the Board of Directors held on Thursday, November 05, 2026, the Board, inter alia, considered and approved the enhancement of the existing Corporate Guarantee in favour of HDFC Bank Limited on behalf of Dryfruit Factory LLP, a Material Subsidiary of the Company, in connection with the credit facilities availed/proposed to be availed by the said LLP, by an additional amount of ₹68,00,000/- (Rupees Sixty-Eight Lakhs Only), thereby increasing aggregate amount of the Corporate Guarantee to ₹5,68,00,000/- (Rupees Five Crores Sixty-Eight Lakhs Only).

   The details as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with the aforesaid SEBI Circular are enclosed herewith as Annexure A.

3. At the meeting of the Board of Directors held on Thursday, November 05, 2026, the Board, inter alia, considered and approved the sale of the Company's immovable property situated at B-1109, Kanakia Wall Street, Chakala, Andheri–Kurla Road, Andheri (East), Mumbai – 400093, Maharashtra, India, and authorised Mr. Viral Desai, Managing Director of the Company, to execute the necessary documents and complete all requisite formalities in this regard.

   The details as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with the aforesaid SEBI Circular are enclosed herewith as Annexure B.

Span Divergent Ltd.
(Formerly Span Diagnostics Ltd.)
9th Floor, Rajhans Bonista,
Behind Ram Chowk, Ghod Dod Road,
Surat - 395 007, Gujarat, India
Phone: +91 261 266 32 32
E-Mail: contact@span.in

4. At the meeting of the Board of Directors held on Thursday, November 05, 2026, the Board, inter alia, considered and approved the leasing of the Company's immovable property situated at 27, Soham Industrial Park, Bareja-Dholka-Mahijada Road, Village Mahijada, Ahmedabad – 382425, Gujarat, to Dryfruit Factory LLP, a Material Subsidiary of the Company, and authorised Mr. Paras Desai, Whole-time Director & CFO to execute the necessary documents and complete all requisite formalities in this regard.

   The details as required under Regulation 30 of the SEBI (LODR) Regulations, 2015 read with the aforesaid SEBI Circular are enclosed herewith as Annexure C.

The Board meeting commenced at 11:15 (IST) and concluded at 17:00 (IST).

You are therefore requested to take the above information on records.

Thanking You.

Yours faithfully,

For Span Divergent Limited

VIRAL PRADIPKUMAR DESAI
Digitally signed by VIRAL PRADIPKUMAR DESAI
Date: 2026.11.05 19:09:28 +05'30'

Viral Desai
Managing Director
DIN 00029219

Span Divergent Ltd.
(Formerly Span Diagnostics Ltd.)
9th Floor, Rajhans Bonista,
Behind Ram Chowk, Ghod Dod Road,
Surat - 395 007, Gujarat, India
Phone: +91 261 266 32 32
E-Mail: contact@span.in

Annexure A

The details as required under Regulation 30 of the SEBI (LODR) Regulations, 2015 read with the SEBI Circular

Issuance of Corporate Guarantee

Sr. No.	Particulars	Description
1	**Name of party for which such guarantees or indemnity or surety was given**	Dryfruit Factory LLP, Material Subsidiary of the Company
2	**Whether the promoter/ promoter group/ group companies have any interest in this transaction? If yes, nature of interest and details thereof and whether the same is done at "arm's length"**	The promoter / promoter group / group companies do not have any interest in this transaction. The Corporate Guarantee has been issued on an arm's length basis.
3	**Brief details of such guarantee or indemnity or becoming a surety viz. brief details of agreement entered (if any) including significant terms and conditions, including amount of guarantee**	The Company has approved issuance of a Corporate Guarantee in favour of HDFC Bank Limited in connection with the credit facilities proposed to be availed by the said LLP, by enhancing the existing Corporate Guarantee by an additional amount of ₹68,00,000/- (Rupees Sixty-Eight Lakhs Only), thereby aggregating the total Corporate Guarantee amount to ₹5,68,00,000/- (Rupees Five Crores Sixty-Eight Lakhs Only).
4	**Impact of such guarantees or indemnity or surety on listed entity**	The said guarantee is provided on behalf of the Material Subsidiary of the Company, which forms part of the consolidated group. At this point, there is no immediate financial impact of guarantee on the Company, other than disclosure in the Financial Statements, and to the extent of the amount for which the corporate guarantee has been provided, in the event Dryfruit Factory LLP is unable to meet its repayment obligations to the Lender. The Corporate Guarantee constitutes a contingent liability for the Company.

Span Divergent Ltd.
(Formerly Span Diagnostics Ltd.)
9th Floor, Rajhans Bonista,
Behind Ram Chowk, Ghod Dod Road,
Surat - 395 007, Gujarat, India
Phone: +91 261 266 32 32
E-Mail: contact@span.in

Annexure B

The details as required under Regulation 30 of the SEBI (LODR) Regulations, 2015 read with the SEBI Circular

Sale of Company's Immovable Property situated at B-1109, Kanakia Wall Street, Chakala, Andheri–Kurla Road, Andheri (East), Mumbai – 400093, Maharashtra, India

Sr. No.	Particulars	Description
1	**The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division of the listed entity during the last financial year**	Not Applicable, as the transaction relates to the sale of an immovable property and not the sale or disposal of any unit or division of the Company.
2	**Date on which the agreement for sale has been entered into**	The Agreement for Sale is proposed to be executed on or before March 31, 2027.
3	**The expected date of completion of sale/disposal**	The sale is expected to be completed on or before March 31, 2027.
4	**Consideration received from such sale/disposal**	The consideration expected to be received from the proposed sale shall not exceed ₹5,00,00,000/- (Rupees Five Crores Only).
5	**Brief details of buyers and whether any of the buyers belong to the promoter/ promoter group/group companies. If yes, details thereof**	M/s. Glorious Sales LLP The Buyer does not belong to the promoter, promoter group or group companies of the Company.
6	**Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arms length"**	The proposed transaction does not fall within the purview of Related Party Transactions.
7	**Additionally, in case of a slump sale, indicative disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slump sale**	Not Applicable

Span Divergent Ltd.
(Formerly Span Diagnostics Ltd.)
9th Floor, Rajhans Bonista,
Behind Ram Chowk, Ghod Dod Road,
Surat - 395 007, Gujarat, India
Phone: +91 261 266 32 32
E-Mail: contact@span.in

Annexure C

The details as required under Regulation 30 of the SEBI (LODR) Regulations, 2015 read with the SEBI Circular
Lease of the Company's immovable property situated at 27, Soham Industrial Park, Bareja-Dholka-Mahijada Road, Village Mahijada, Ahmedabad – 382425, Gujarat

Sr. No.	Particulars	Details of the Transaction
1	**Name of the entity with whom agreement/lease is signed**	Dryfruit Factory LLP, Material Subsidiary of the Company.
2	**Area/Size and location of the property leased out**	27, Soham Industrial Park, Bareja-Dholka-Mahijada Road, Village Mahijada, Ahmedabad – 382425, Gujarat
3	**Whether the counterparty belongs to the promoter / promoter group / group companies. If yes, details thereof**	Yes. Dryfruit Factory LLP, Material Subsidiary of the Company.
4	**Nature of relationship with the listed entity**	Material Subsidiary of the Company
5	**Purpose / Objective of the lease**	To facilitate cashew processing/manufacturing operations and/or use as a commercial office by the Material Subsidiary of the Company
6	**Significant terms and conditions of the agreement in brief**	The Lease Agreement is proposed to be executed on or before December 31, 2026, subject to mutually agreed terms and conditions.
7	**Quantum of lease rent / consideration to be received**	Expected Rental Income: Not exceeding ₹3,00,000/- (Rupees Three Lakhs Only) per month.
8	**Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length"**	Yes, the transaction constitutes a Related Party Transaction. The transaction is being undertaken on an arm's length basis and has been approved by the Audit Committee and the Board of Directors of the Company.

Span Divergent Ltd.
(Formerly Span Diagnostics Ltd.)
9th Floor, Rajhans Bonista,
Behind Ram Chowk, Ghod Dod Road,
Surat - 395 007, Gujarat, India
Phone: +91 261 266 32 32
E-Mail: contact@span.in

9	**Whether the lease or disposal of the undertaking is outside the Scheme of Arrangement? If yes, compliance with Regulation 37A**	Not Applicable. The transaction relates to the leasing of immovable property to a Material Subsidiary of the Company and does not constitute a sale or disposal of the whole or substantially the whole of an undertaking under Regulation 37A of the SEBI (LODR) Regulations, 2015.
10	**Any other disclosures related to such agreements / financial impact**	The transaction is expected to generate lease rental income for the Company of up to ₹3,00,000/- (Rupees Three Lakhs Only) per month. The transaction is not expected to have any adverse impact on the business operations or financial position of the Company.

Span Divergent Limited

(Formerly known as Span Diagnostics Limited)

Regd.Office : 9th Floor,902-904, Rajhans Bonista, Behind Ram Chowk Temple,Ghod Dod Road, Surat-395007

CIN:L74999GJ1980PLC003710, Website: www.span.in

Statement of unaudited Financial Results for the Quarter and Half Year ended September 30, 2026.

(Rs. In Lakhs)

Sr. No	Particulars	Standalone					
		Three Months			Six Months		Year ended March 31, 2026
		Quarter ended September 30, 2026	Quarter ended June 30, 2026	Quarter ended September 30, 2025	Half Year ended September 30, 2026	Half Year ended September 30, 2025	
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income from operations						
	Other Operating Income	16.35	13.45	36.57	29.80	75.02	146.64
	Other income	20.11	17.38	19.27	37.48	45.75	75.78
	Total income	36.46	30.83	55.84	67.28	120.77	222.42
2	Expenses						
	Employee benefit expense	34.45	26.39	30.44	60.84	57.36	122.76
	Finance costs	0.36	0.42	-	0.78	-	2.16
	Depreciation and amortisation expense	5.69	5.75	6.44	11.44	12.72	25.80
	Other expenses	22.33	14.00	7.75	36.33	15.73	40.24
	Total expenses	62.83	46.56	44.63	109.39	85.81	190.96
3	Profit / (Loss) before exceptional items, Prior Period items and tax (1-2)	(26.37)	(15.73)	11.21	(42.11)	34.96	31.46
4	Exceptional items	3.00	(13.20)	0.30	(10.20)	19.30	(41.10)
5	Profit/(Loss) before tax (3-4)	(29.37)	(2.53)	11.51	(31.91)	54.26	72.56
6	Tax expense:						
	- Current tax	-	-	-	-	-	-
	- Deferred tax	(2.31)	1.69	(0.50)	(0.62)	0.57	(0.08)
7	Profit/(Loss) for the period after tax (5-6)	(27.06)	(4.22)	12.01	(31.29)	53.69	72.64
8	Other comprehensive income						
	Item that will not be reclassified to Profit or Loss (Consisting of re-measurement of net defined benefit	3.28	(0.63)	(0.18)	2.65	(0.36)	5.29
	Income tax relating to items that will not be reclassified to Profit or Loss	(0.75)	0.14	0.05	(0.61)	0.10	(1.21)
9	Total comprehensive income for the year (7+8)	(24.53)	(4.71)	11.88	(29.25)	53.43	76.72
10	Paid-up equity share capital (Face value of Rs. 10/- each)	726.32	726.32	546.17	726.32	546.17	726.32
11	Other Equity						3,366.89
12	Weightage Average No of Paid-up Equity Shares	7,263,228	7,263,228	7,263,228	72,632,280	5,461,747	5,481,489
13	Earnings per equity share for profit from operation attributable to owners of the entity:						
14	Basic earnings per share	(0.37)	(0.06)	0.17	(0.04)	0.98	1.33
15	Diluted earnings per share	(0.37)	(0.06)	0.17	(0.04)	0.98	1.33

SPAN DIVERGENT LIMITED * SURAT

Note :

1. Statement of Assets and Liabilities as at September 30, 2026 and March 31, 2026 is given below:

Rs. In Lakh

Particulars	Standalone	
	As at September 30, 2026	As at March 31, 2026
Non-current assets		
Property, plant and equipment	287.45	295.24
Right-of-use-assets	14.97	20.25
Other intangible assets	2.49	2.44
Financial assets		
i. Investments Non-current assets	3,829.71	3,208.16
ii. Others	20.50	8.80
Deferred tax assets (Net)	11.26	11.34
Other non-current assets		
Total non-current assets	**4,166.38**	**3,546.23**
Current assets		
Financial assets		
i. Investments Current assets	439.83	465.74
ii. Trade receivables Current assets	24.58	27.72
iii.Cash and cash equivalents	1.73	585.23
iii.Bank balances other than (iii) above	-	-
v. Loans Current assets	-	-
iv. Others Current assets	35.95	2.14
Current tax Assets (Net)	31.08	28.67
Other current assets	4.89	1.29
Assets classified as held for sale	-	-
Total current assets	**538.06**	**1,110.78**
TOTAL	**4,704.44**	**4,657.02**
EQUITY AND LIABILITIES		
Equity		
Equity share capital/Partners capital	726.32	726.32
Other equity	3,366.89	3,396.15
Total equity	**4,093.21**	**4,122.46**
LIABILITIES		
Non-current liabilities		
Financial Liabilities		
i. Lease Liabilities	9.91	9.13
ii. Other financial liabilities Non-current liabilities	-	-
Provisions Non-current liabilities	66.80	65.22
Deferred tax liabilities (Net)	31.07	31.17
Total non-current liabilities	**107.78**	**105.52**
Current liabilities		
Financial liabilities		
i. Borrowings Current liabilities	243.20	192.20
ii. Lease liabilities	5.94	11.89
iii. Trade payables Current liabilities		
A) total outstanding dues of micro enterprises and small enterprises; and	-	0.05
B) total outstanding dues of creditors other than micro enterprises and small enterprises	3.86	7.54
iv. Other financial liabilities Current liabilities	203.82	175.18
Other current liabilities	4.28	2.41
Provisions Current liabilities	42.35	39.76
Total current liabilities	**503.45**	**429.03**
Total liabilities	**611.23**	**534.55**
TOTAL	**4,704.44**	**4,657.02**

SPAN DIVERGENT LIMITED SURAT

Notes:

2 Figures for the quarter ended September 30, 2026 are the balancing figures between the reviewed figures till September 30, 2026 and reviewd figures up-to the first quater of the relavent financial year.

3 As required under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirments) Regulations, 2015, the statutory auditors have conducted a limited review of the above results for the quarter ended September 30, 2026.

4 The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on November 05, 2026.

5 Other Operating Income comprises of Interest on fluctuating capital provided by the Company to its LLP subsidiaries and management fees income which is based on the revenue earned by subsidiaries during the period.

6 In case of subsidiary:

a) Aranya Consulting and Biotech LLP, w.e.f May19, 2026 (Formerly, Aranya Agri Biotech LLP) had accumulated losses of Rs. 1495 Lakhs till March 31 2026 and loss of Rs.1.37 Lakhs in the current year, up to September 30, 2026. The Board has approved the plan to revive the operations of LLP from its non operational state, in light of potential of new opportunities emerging and accordingly the assets of LLP has been reclassified as part of PPE.

(b) Biospan Scientific LLP had accumulated losses of Rs.157 Lakhs as at 31st March 2019, resulting in substantial erosion of the net worth of the LLP. Hence the Management had decided to impair the investment and Rs. 183 Lakhs were provided in the books of the Company and was treated as an exceptional item during the year 2018-19. Notwithstanding the above, the financial results of the LLP has been prepared on going concern basis as Management is exploring the possibilities to revive the LLP on its own or by entering in to business tie-ups and it endeavours to be able to establish profitable operation.

(c) Biospan Contamination Control Solution Pvt. Ltd had accumulated losses of Rs.769 Lakhs till September 30, 2026. As on that date the subsidiary Company's total liabilities exceeded its total assets by Rs. 759 Lakhs. Notwithstanding the above, the financial results of the subsidiary Company has been prepared on going concern basis as Management believes that the company would be able to establish profitable operation and the losses incurred is attributable to factors of temporary nature. Further, Management is confident that with appropriate product introductions, the Company will achieve adequate revenue and negative net worth would turn positive in short term horizon.

7 Previous periods figures have been regrouped and rearranged wherever necessary.

SPAN DIVERGENT LIMITED * SURAT

For, Span Divergent Limited

Viral P. Desai
Managing Director
DIN : 00029219

Place : Surat
Date : November 05, 2026

Span Divergent Limited standalone

8. Statement of Cash Flows for the Halfyear ended September 30, 2026.

Particular	Year ended September 30, 2026	Year ended March 31, 2026
Profit before income tax	**(31.91)**	**72.56**
Adjustments for		-
Depreciation and amortisation expense	11.44	25.80
Un realised Loss/(Gain) on Investments	9.18	(14.33)
Rental Income	(9.43)	(40.40)
Interest Income	(0.50)	(1.91)
Gain on Sale of Investments	(17.90)	(17.25)
Gain on Sale of Assets	1.64	(0.05)
Financial Guarantee Fees Income	(2.51)	(1.84)
Reveral of Impairment in subsidiaries	(10.20)	(41.10)
Change in operating assets and liabilities:		
(Increase)/Decrease in trade receivables-Current	3.14	5.35
Increase in trade payables- current	(3.73)	2.76
(Increase) in other financial assets-current	(33.81)	9.12
(Increase)/decrease in other current assets	(3.60)	(0.48)
Increase/(decrease) in provisions-Non Current	4.24	6.01
Increase/(decrease) in provisions-Current	2.59	4.64
Increase/(decrease) in other financial liabilities-current	28.64	16.45
Increase in other current liabilities	1.87	(2.06)
Cash generated from operations	(50.84)	23.27
Income taxes paid	2.42	17.49
Net cash inflow from operating activities	(53.26)	5.78
Cash flows from investing activities		
(Purchase)/Redemption of investments in Subsidiary	(611.36)	(235.25)
Proceeds from sale of investments	34.63	149.02
Proceeds from Maturity of Fixed Deposit	(11.70)	27.20
(Purchase)/Sale of property, plant and equipment	(0.06)	(5.65)
Rental Income	9.43	40.40
Interest received	3.00	3.75
Net cash outflow from investing activities	**(576.07)**	**(20.53)**
Cash flows from financing activities		
Proceeds/(Repayment to) from borrowings	51.00	-
Changes in Lease Liabilities	(5.16)	(9.73)
Proceeds from Issue of Equity Shares on Preferential Basis	-	567.65
Net cash inflow (outflow) from financing activities	**45.84**	**557.92**
Net increase (decrease) in cash and cash equivalents	(583.49)	543.17
Cash and cash equivalents at the beginning of the financial year	**585.23**	**42.06**
Cash and cash equivalents at end of the year	**1.74**	**585.23**
Reconciliation of cash and cash equivalents as per the cash flow statement		
Cash and cash equivalents as per above comprise of the following		

Particulars	Year ended September 30, 2026	Year ended March 31, 2026
Balances with banks		
- in current accounts	1.68	585.21
Cash on hand	0.06	0.02
Balances per statement of cash flows	**1.74**	**585.23**

SPAN DIVERGENT LIMITED * SURAT

Span Divergent Ltd.
(Formerly Span Diagnostics Ltd.)

9th Floor, Rajhans Bonista,
Behind Ram Chowk, Ghod Dod Road,
Surat - 395 007, Gujarat, India
Phone: +91 261 266 32 32

B. STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF PUBLIC ISSUE, RIGHTS ISSUE, PREFERENTIAL ISSUE, QUALIFIED INSTITUTIONS PLACEMENT ETC – APPLICABLE (ANNEXURE ATTACHED)

Note: The Company had raised funds through a Preferential Issue in March 2026. During the quarter ended September 30, 2026, the proceeds of the Preferential Issue allocated towards the specified objects of the issue have been fully utilised. Accordingly, there is no deviation or variation in the utilisation of the proceeds of the Preferential Issue from the objects stated in the offer documents.

C. FORMAT FOR DISCLOSING OUTSTANDING DEFAULT ON LOANS AND DEBT SECURITIES – NOT APPLICABLE AS NO DEFAULT

D. FORMAT FOR DISCLOSURE OF RELATED PARTY TRANSACTIONS (applicable only for half-yearly filings i.e., 2nd and 4th quarter) – APPLICABLE

E. STATEMENT ON IMPACT OF AUDIT QUALIFICATIONS (FOR AUDIT REPORT WITH MODIFIED OPINION) SUBMITTED ALONGWITH ANNUAL AUDITED FINANCIAL RESULTS (Standalone and Consolidated separately) (applicable only for Annual Filing i.e., 4th quarter) - NOT APPLICABLE

SPAN DIVERGENT LIMITED * SURAT

STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF PUBLIC ISSUE, RIGHTS ISSUE, PREFERENTIAL ISSUE, QUALIFIED INSTITUTIONS PLACEMENT ETC.

Statement of Deviation / Variation in utilization of funds raised	
Name of listed entity	Span Divergent Limited
Mode of Fund Raising	Preferential Issue
Date of Raising Funds	March 28, 2026 i.e. Date of allotment
Amount Raised	INR 579.36 Lakhs
Report filed for Quarter ended	September 30, 2026
Monitoring Agency	Notapplicable
Monitoring Agency Name, if applicable	Not Applicable
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	Not Applicable
If Yes, Date of shareholder Approval	Not Applicable
Explanation for the Deviation / Variation	-
Comments of the Audit Committee after review	-
Comments of the auditors, if any	-

Objects for which funds have been raised and where there has been a deviation, in the following table

Original Object	Modified Object, if any	Original Allocation	Modified allocation, if any	Funds Utilised	Amount of Deviation/Variation for the quarter according to applicable object	Remarks if any
Procurement of Raw Cashew Nut (RCN) Inventory (2 - 3 Months upfront)	NA	500.00 Lakhs	0.00	500.00 Lakhs	0.00	Refer Note 1
Restart and Ramp-up Costs (Commissioning & Operational Mobilisation)	NA	50.00 Lakhs	0.00	50.00 Lakhs	0.00	
Selective Refurbishment for Productivity and Quality	NA	29.36 Lakhs	0.00	29.36 Lakhs	0.00	

Note 1: The Company had raised funds through a Preferential Issue in March 2026. During the quarter ended September 30, 2026, the proceeds of the Preferential Issue allocated towards the specified objects of the issue have been fully utilised. Accordingly, there is no deviation or variation in the utilisation of the proceeds of the Preferential Issue from the objects stated in the offer documents.

Deviation or variation could mean:

(a) Deviation in the objects or purposes for which the funds have been raised or

(b) Deviation in the amount of funds actually utilized as against what was originally disclosed or

(c) Change in terms of a contract referred to in the fund raising document i.e. prospectus, letter of offer, etc

FOR SPAN DIVERGENT LIMITED

VIRAL DESAI
MANAGING DIRECTOR
DIN 00029219

SPAN DIVERGENT LIMITED * SURAT

Span Divergent Limited

(Formerly known as Span Diagnostics Limited)

Regd.Office : 9th Floor,902-904, Rajhans Bonista, Behind Ram Chowk Temple,Ghod Dod Road, Surat-395007

CIN:L74999GJ1980PLC003710, Website: www.span.in

Statement of Consolidated unaudited Financial Results for the Quarter and Half Year ended September 30,2026.

Sr. No.	Particulars	Consolidated					
		Three Months			Six Months		Year ended March 31, 2026
		Quarter ended September 30, 2026	Quarter ended June 30, 2026	Quarter ended September 30, 2025	Half Year ended September 30, 2026	Half Year ended September 30, 2025	
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income from operations						
	Sale of Traded Products/Services	536.16	88.63	756.63	624.79	852.86	1,689.50
	Other Operating Income	5.25	13.25	7.80	18.50	18.60	32.96
	Other income	67.30	28.32	21.83	95.61	94.01	128.62
	Total income	608.71	130.20	786.26	738.90	965.47	1,851.08
2	Expenses						
	Cost of materials consumed	-	-	-	-		-
	Purchases of stock-in-trade	387.69	478.01	645.46	865.70	1,069.44	1,630.37
	Changes in inventories of work-in-progress, stock-in-trade and finished goods	45.23	(402.69)	(2.56)	(357.46)	(356.79)	(72.85)
	Employee benefit expense	68.29	46.95	53.84	115.24	105.00	214.57
	Finance costs	16.22	13.67	11.88	29.89	26.45	43.26
	Depreciation and amortisation expense	34.57	24.38	26.69	58.95	51.27	117.25
	Other expenses	132.94	84.45	67.74	217.38	120.34	208.97
	Total expenses	684.94	244.77	803.05	929.70	1,015.71	2,141.57
3	Profit / (Loss) before tax and Exceptional items (1-2)	(76.23)	(114.57)	(16.79)	(190.80)	(50.24)	(290.49)
4	Exceptional items		-	0.30		19.30	-
5	Profit/(Loss) before tax (3-4)	(76.23)	(114.57)	(16.49)	(190.80)	(30.94)	(290.49)
6	Tax expense:						
	- Current tax	-	-	-	-	-	-
	- Deferred tax	(0.95)	4.25	2.28	3.30	4.84	4.23
7	Profit/(Loss) for the period after tax (5-6)	(75.28)	(118.82)	(18.77)	(194.10)	(35.78)	(294.72)
	Profit for the year attributable to:						
	(a) Owners of the Company	(64.75)	(105.18)	(13.43)	(169.94)	(23.26)	(250.15)
	(b) Non Controlling Interest	(10.53)	(13.64)	(5.34)	(24.16)	(12.52)	(44.57)
		(75.28)	(118.81)	(18.77)	(194.10)	(35.78)	(294.72)
8	Other comprehensive income						
	Item that will not be reclassified to Profit or Loss (Consisting of re-measurement of net defined benefit liabilities)	2.81	(1.10)	(0.005)	1.71	(0.01)	3.42
	Income tax relating to items that will not be reclassified to Profit or Loss	(0.59)	0.31	0.005	(0.28)	0.01	(1.26)
	Other comprehensive income	2.22	(0.79)	(0.00)	1.43	0.02	2.16
	Other comprehensive income attributable to:						
	(a) Owners of the Company	2.22	(0.77)	0.05	1.43	0.09	2.10
	(b) Non Controlling Interest	(0.00)	(0.02)	(0.05)	(0.00)	(0.11)	0.06
		2.22	(0.79)	(0.00)	1.43	(0.01)	2.16
9	Total comprehensive income for the year (7+8)	(73.06)	(119.60)	(18.77)	(192.67)	(35.78)	(292.56)
	Total comprehensive income attributable to:						
	(a) Owners of the Company	(62.53)	(105.99)	(13.48)	(168.51)	(23.37)	(247.94)
	(b) Non Controlling Interest	(10.53)	(13.62)	(5.29)	(24.17)	(12.41)	(44.62)
		(73.06)	(119.61)	(18.77)	(192.67)	(35.78)	(292.56)
10	Paid-up equity share capital (Face value of Rs. 10/- each)	726.32	726.32	546.17	726.32	546.17	726.32
11	Other Equity						759.61
	Earnings per equity share for profit from operation attributable to owners of the entity:						
12	Basic earnings per share *	(1.04)	(1.64)	(0.34)	(2.67)	(0.66)	(5.38)
13	Diluted earnings per share *	(1.04)	(1.64)	(0.34)	(2.67)	(0.66)	(5.38)

* For the period only and not annualised

SPAN DIVERGENT LIMITED * SURAT

Note : -

1 The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on November 05, 2026.

2 As required under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirments) Regulations, 2015, the statutory auditors have conducted a limited review of the above results for the quarter ended September 30, 2026.

3 The financial results of the Company have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under Section 133 of the Companies Act, 2013 read with the relevant rules of the Companies (Indian Accounting Standards) Rules, 2015 as amended by the Companies (Indian Accounting Standards)(Amendment) Rules, 2016.

4 In case of subsidiary:
a) Aranya Consulting and Biotech LLP, w.e.f May19, 2026 (Formerly, Aranya Agri Biotech LLP) had accumulated losses of Rs. 1495 Lakhs till March 31 2026 and loss of Rs.1.37 Lakhs in the current year, up to September 30, 2026. The Board has approved the plan to revive the operations of LLP from its non operational state, in light of potential of new opportunities emerging and accordingly the assets of LLP has been reclassified as part of PPE.
(b) Biospan Scientific LLP had accumulated losses of Rs.157 Lakhs as at 31st March 2019, resulting in substantial erosion of the net worth of the LLP. Hence the Management had decided to impair the investment and Rs. 183 Lakhs were provided in the books of the Company and was treated as an exceptional item during the year 2018-19. Notwithstanding the above, the financial results of the LLP has been prepared on going concern basis as Management is exploring the possibilities to revive the LLP on its own or by entering in to business tie-ups and it endeavours to be able to establish profitable operation.
(c) Biospan Contamination Control Solution Pvt. Ltd had accumulated losses of Rs.769 Lakhs till September 30, 2026. As on that date the subsidiary Company's total liabilities exceeded its total assets by Rs. 759 Lakhs. Notwithstanding the above, the financial results of the subsidiary Company has been prepared on going concern basis as Management believes that the company would be able to establish profitable operation and the losses incurred is attributable to factors of temporary nature. Further, Management is confident that with appropriate product introductions, the Company will achieve adequate revenue and negative net worth would turn positive in short term horizon.

5 Previous quarters and periods figures have been regrouped and rearranged wherever necessary.

For, Span Divergent Limited

SPAN DIVERGENT LIMITED * SURAT

Viral P. Desai
Managing Director
DIN : 00029219

Place : Surat
Date : November 05, 2026.

SPAN DIVERGENT LIMITED

(Formerly known as Span Diagnostics Limited)

6. Consolidated Balance Sheet at the Year ended March 31, 2026.

Particulars	As at September 30, 2026	As at March 31, 2026
	Unaudited	(Audited)
ASSETS		
Non-current assets	-	-
Property, plant and equipment	971.16	910.69
Right-of-use-assets	118.98	20.25
Investment properties	-	-
Intangible assets	2.50	2.46
Financial assets	-	-
i. Investments	-	-
ii. Trade Receivables	-	-
ii. Loans	-	-
i. Others	20.50	8.80
Deferred tax assets (Net)	35.93	36.46
Other non-current assets	-	-
Total non-current assets	**1,149.07**	**978.66**
Current assets		
Inventories	530.60	172.33
Financial assets		
i. Investments	490.94	515.43
ii. Trade receivables	275.80	154.02
iii. Cash and cash equivalents	84.36	647.68
iv. Bank balances other than (iii) above	50.27	49.50
v. Others	43.27	11.92
vi. Other Financial Assets	31.08	28.67
Current tax Assets (Net)	1.35	10.93
Other current assets	419.85	321.10
Total current assets	**1,927.52**	**1,911.58**
Total assets	**3,076.59**	**2,890.24**
EQUITY AND LIABILITIES		
Equity		
Equity share capital	726.32	726.32
Other equity	591.10	759.61
Non Controling Interest	(527.38)	(503.22)
	790.04	**982.71**
LIABILITIES		
Non-current liabilities		
Financial Liabilities		
i. Borrowings	-	-
ii. Leasse Liability	93.18	9.13
Provisions	90.57	84.20
Deferred tax liabilities (Net)	52.35	49.30
Other non-current liabilities	22.37	23.87
Total non-current liabilities	**258.47**	**166.50**
Current liabilities		
Financial liabilities		
i. Borrowings	1,045.24	692.67
ii. Lease liabilities	29.94	11.89
iii. Trade payables	-	
A) total outstanding dues of micro enterprises and small enterprises; and	5.17	11.73
B) total outstanding dues of creditors other than micro enterprises and small enterprises	526.94	568.84
iv. Other financial liabilities	228.38	192.72
Other current liabilities	104.37	180.36
Provisions	88.04	82.82
Current tax liabilities	-	-
Total current liabilities	**2,028.08**	**1,741.03**
Total liabilities	**2,286.55**	**1,907.53**
Total equity and liabilities	**3,076.59**	**2,890.24**

SPAN DIVERGENT LIMITED SURAT

7. Span Divergent Limited Consolidated Cash Flow Statement as at September 30, 2026

Particulars	As at September 30, 2026	As at March 31, 2026
Profit before income tax	(190.80)	(290.49)
Adjustments for		
Depreciation and amortisation expense	58.95	117.25
Rental Income	(11.92)	(45.38)
Interest Income	(4.58)	(6.28)
Gain on Sale of Investments	(17.90)	(17.25)
Unrealised Gain Loss on Biological Assets/Investments	0.79	(17.21)
Loss on Dissolution of Subsidiary Firm	-	0.60
Finance Cost	29.89	43.26
Balances Written Back	(0.18)	(16.87)
(Gain)/Loss on Sale property, plant and equipment	(1.52)	(0.05)
Penalties & Interest	-	1.27
Change in operating assets and liabilities:		
(Increase)/Decrease in trade receivables- current	(121.78)	(15.36)
(Increase)/Decrease in Inventory- current	(358.27)	(72.39)
Increase in trade payables-current	(48.46)	234.90
(Increase) in other financial assets-non-current	(11.70)	27.20
(Increase) in other financial assets-current	(31.34)	9.67
(Increase)/decrease in other current assets	(98.74)	(97.75)
Increase/(decrease) in provisions- non current	6.37	1.81
Increase/(decrease) in provisions- current	5.21	(1,585.63)
Increase/(decrease) in other financial liabilities-current	35.66	19.35
Increase in other current liabilities-non current	82.55	12.71
Increase in other current liabilities-current	(57.93)	(154.65)
Cash generated from operations	(735.70)	(1,851.30)
Income taxes paid	9.04	(18.46)
Reversal of Impairment Loss	-	1,631.03
Adjustment of Non-Controlling Interest	-	144.86
Adjustment of Consolidation	-	115.50
Net cash inflow from operating activities	(726.66)	21.63
Cash flows from investing activities		
Proceeds / (Purchase) from sale of investments	40.83	144.58
Proceeds from sale/(Purchase) of property, plant and equipment	(216.67)	(41.19)
Rental Income	11.92	45.38
Interest received	4.58	6.28
Net cash outflow from investing activities	(159.34)	155.05
Cash flows from financing activities		
Proceeds/Repayment from borrowings	352.57	(111.91)
Proceeds from Issue of Equity Shares on Preferential Basis	-	567.65
Interest paid	(29.89)	(43.26)
Net cash inflow (outflow) from financing activities	322.68	412.48
Net increase (decrease) in cash and cash equivalents	(563.32)	589.16
Cash and cash equivalents at the beginning of the financial year	647.68	58.52
Cash and cash equivalents at end of the year	84.36	647.68
Reconciliation of cash and cash equivalents as per the cash flow statement		
Cash and cash equivalents as per above comprise of the following		

Particulars	As at September 30, 2026	As at March 31, 2026
Balances with banks and Cash on hand	84.36	647.68
Balances per statement of cash flows	84.36	647.68

SPAN DIVERGENT LIMITED * SURAT

8. Consolidated Segment Revenue, Results Assets and Liability as at September 30, 2026.

(Rs. In Lakhs)

Sr. No.	Particulars	Three Months			Six Months		Year ended March 31, 2026
		Quarter ended September 30, 2026	Quarter ended March 31, 2026	Quarter ended September 30,2025	Half Year ended September 30 2026	Half Year ended September 30, 2025	
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	**Segment Revenue**						
	- Cashew processing	536.17	379.56	657.70	571.58	672.98	1,367.57
	- Tissu Culture	-	2.09	-	-	-	24.94
	- Trading	53.17	81.30	104.26	120.31	215.60	364.16
	Gross Revenue from Operations from Segments	**589.34**	**462.95**	**761.96**	**691.89**	**888.58**	**1,756.67**
	Less : Inter Segment Revenue	-	-	-	-	-	-
	Net Revenue from Operations from Segments	**589.34**	**462.95**	**761.96**	**691.89**	**888.58**	**1,756.67**
2	**Segment Results**						
	Profit / (Loss) before Interest and tax						
	- Cashew processing	(18.10)	(75.54)	(23.27)	(100.03)	(89.18)	(269.22)
	- Tissu Culture	(0.10)	-	-	(0.21)	-	-
	- Trading	(28.54)	(33.71)	(5.75)	(48.45)	(17.01)	(73.89)
	- Unallocable Income over expenses like (Including HO)	(29.49)	(3.85)	12.53	(42.11)	75.25	52.62
	Total Profit / (Loss) before Tax	**(76.23)**	**(113.10)**	**(16.49)**	**(190.80)**	**(30.94)**	**(290.49)**
3	**Segment Assets**						
	- Cashew processing	1,799.63	926.85	1,321.03	1,799.63	1,321.03	926.85
	- Tissu Culture	68.28	69.94	70.57	68.28	70.57	69.94
	- Trading	358.22	456.97	455.65	358.22	455.65	456.97
	- Unallocable	850.46	1,436.48	909.71	850.46	909.71	1,436.48
	Total Assets	**3,076.59**	**2,890.24**	**2,756.96**	**3,076.59**	**2,756.96**	**2,890.24**
4	**Segment Liability**						
	- Cashew processing	691.30	336.51	642.61	691.30	642.61	336.51
	- Tissu Culture	9.94	10.23	9.69	9.94	9.69	10.23
	- Trading	998.36	1,038.61	959.17	998.36	959.17	1,038.61
	- Unallocable	586.95	522.18	2,065.41	586.95	2,065.41	522.18
	Total Liability	**2,286.55**	**1,907.53**	**3,676.87**	**2,286.55**	**3,676.88**	**1,907.53**

SPAN DIVERGENT LIMITED * SURAT

For, Span Divergent Limited

Viral Desai
Managing Director
DIN: 00029219

Place : Surat
Date : November 05, 2026.

Y. B. DESAI & ASSOCIATES
CHARTERED ACCOUNTANTS

0261 : 2474242
0261 : 2465851
0261 : 2465852
Email: mail@ybdesaica.com

1 / 573, 1st FLOOR, GAJANAND COMPLEX, POR MOHALLOW, NEAR ANAND HOSPITAL, NANPURA, SURAT - 395 001.

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to

To the Board of Directors of

Span Divergent Ltd.

1. We have reviewed the accompanying statement of unaudited standalone financial results of **Span Divergent Limited** ("the Company") for the quarter ended **September 30, 2026** and year to date from April 01, 2026 to September 30, 2026 (the "statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2. This Statement, which is the responsibility of the Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Y. B. Desai & Associates * Chartered Accountants * SURAT-1

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Y. B. Desai and Associates
Chartered Accountants
Firm Registration No. 102368W



Mayank Y. Desai
Partner
Membership No. :- 108310

UDIN: 26108310TKOAOU8379

Date :- 05th November, 2026

Place :-Surat

Y. B. DESAI & ASSOCIATES
CHARTERED ACCOUNTANTS

0261 : 2474242
0261 : 2465851
0261 : 2465852
Email: mail@ybdesaica.com

1 / 573, 1st FLOOR, GAJANAND COMPLEX, POR MOHALLOW, NEAR ANAND HOSPITAL, NANPURA, SURAT - 395 001.

Independent Auditor's Review Report on Quarterly and Year to Date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

Review Report to

The Board of Directors

Span Divergent Ltd.

1. We have reviewed the accompanying statement of Unaudited Consolidated Financial Results of **Span Divergent Limited** ('the Holding Company') and its subsidiary (the Holding Company and its subsidiary together referred to as 'the Group'), for the quarter ended September 30, 2026 and year to date from **April 01, 2026 to September 30, 2026** (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended including (the "Listing Regulation").

2. This Statement, which is the responsibility of the Holding Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Holding Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance Circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, to the extent applicable.

4. The Statement includes the results of the following entities:

   Parent Company:

   i. Span Divergent Limited

Y. B. Desai & Associates * SURAT * Chartered Accountants

Subsidiary:

- Dryfruit Factory LLP
- Aranya Consulting and Biotech LLP
- Biospan Scientific LLP
- Biospan Contamination Control Solutions Pvt Ltd

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ("Ind AS") specified under section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulation, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. The accompanying Statement includes the unaudited interim financial results and other unaudited financial information, in respect of subsidiary have been reviewed by their respective independent auditor.

   The independent auditor's reports on interim financial results of this entity have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures in respect of this subsidiary, is based solely on the report of such auditor and procedures performed by us as stated in paragraph 3 above.

   Our conclusion on the Statement in respect of above matter is not modified with respect to our reliance on the work done and the reports of the other auditor.

For Y. B. Desai and Associates
Chartered Accountants
Firm Registration No. 102368W



Mayank Y. Desai
Partner
Membership No. :- 108310

UDIN: 26108310QJAYIX6682

Date :- 05th November, 2026

Place :-Surat